Novavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year. However, the ...

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...

Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.

Novavax, Inc. (NVAX) shares surged 17.4% after reporting fourth-quarter 2025 revenues of $147.14 million, surpassing the Zacks Consensus Estimate by 87.65%. The J. M. Smucker Company (SJM) ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

Recognized $625 million in primarily non-cash revenue in 2025 following the resolution of historical APA agreements with ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Novavax shares jump 21% after posting a surprise profit and 67% revenue growth, while outlining lower 2026 revenue guidance.

Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. The stock leapt 16% to $11.03 in Thursday afternoon trading, ...

Novavax Inc (NASDAQ:NVAX) stock is powering past the chop, last seen up 25.1% to trade at $11.93. The drugmaker reported a beat-and-raise in the earnings confessional, thanks in part to its ...